芪龙祛瘀合剂治疗急性缺血性脑卒中(气虚血瘀型)的疗效评价  

Efficacy evaluation on Qilong Quyu Mixture in the treatment of acute ischemic stroke (syndrome of qi deficiency and blood stasis)

作　　者：张红智[1] 龚帆[1] 唐海燕[1] 王骏[1] 秦保锋[1] 郭咏梅[1] 俞晓飞[1] ZHANG Hongzhi;GONG Fan;TANG Haiyan;WANG Jun;QIN Baofeng;GUO Yongmei;YU Xiaofei(Department of Encephalopathy,Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine,Shanghai 201203,China)

机构地区：[1]上海中医药大学附属曙光医院脑病科,上海201203

出　　处：《上海中医药大学学报》2021年第3期23-27,共5页Academic Journal of Shanghai University of Traditional Chinese Medicine

基　　金：上海市卫健委卫生行业临床研究专项项目(201940212);上海市中医药三年行动计划“杏林新星”人才培养项目(ZY3-RCPY-2-2073);上海市中医重点专科(中医脑病科)培育项目(沪卫中管[2019]7号)。

摘　　要：目的:观察芪龙祛瘀合剂治疗急性缺血性脑卒中(气虚血瘀型)患者的临床疗效。方法:纳入急性缺血性脑卒中(气虚血瘀型)患者124例,随机分为治疗组和对照组,每组各62例。两组患者均给予西医常规治疗,在此基础上,治疗组患者给予芪龙祛瘀合剂口服,对照组患者给予安慰剂口服,治疗周期为28 d,治疗后随访90 d。治疗前后及随访90 d时,评价两组患者的美国国立卫生研究院卒中量表(NIHSS)、改良Rankin量表(mRS)、Barthel指数(BI)评分;随访90 d时评价并比较两组患者的临床疗效;比较两组患者在治疗及随访期间的缺血性脑卒中复发情况。结果:研究过程中,治疗组剔除或脱落4例,对照组剔除或脱落2例,最终治疗组58例、对照组60例纳入统计分析。(1)治疗后及随访90 d时,两组患者的NIHSS评分较治疗前均明显降低(P<0.01),且治疗组患者的评分均低于对照组(P<0.05,P<0.01)。(2)治疗后及随访90 d时,两组患者的mRS评分较治疗前均明显改善(P<0.05),且治疗组患者的mRS评分改善情况优于对照组(P<0.05)。(3)治疗后及随访90 d时,两组患者的BI评分较治疗前均明显升高(P<0.01),且治疗组患者的评分均高于对照组(P<0.01)。(4)随访90 d时,治疗组患者的临床总有效率为93.1%,对照组为78.3%,治疗组的疗效优于对照组(P<0.05)。(5)治疗及随访期间,治疗组的复发率为3.4%,对照组为8.3%,组间比较差异无统计学意义(P>0.05)。结论:芪龙祛瘀合剂联合西医常规疗法治疗急性缺血性脑卒中(气虚血瘀型),能够更好地改善患者的神经功能缺损程度,降低患者的残障等级,提高日常生活活动能力。Objective:To observe the clinical efficacy of Qilong Quyu Mixture in treating patients of acute ischemic stroke with syndrome of qi deficiency and blood stasis.Methods:A total of 124 patients of acute ischemic stroke with syndrome of qi deficiency and blood stasis were included and randomly divided into the treatment group and control group,62 cases in each group.The patients in both groups were treated with conventional western medicine.Based on above,the patients in the treatment group were orally treated with Qilong Quyu Mixture and the patients in the control group were orally treated with placebo.The course of treatment was 28 days and the follow-up after treatment was 90 days.Before and after treatment and on the 90 th day of follow-up,the scores of National Institute of Health stroke scale(NIHSS),modified Rankin scale(mRS)and Barthel index(BI)were evaluated in both groups.On the 90 th day of follow-up,the clinical efficacy of the two groups was evaluated and compared.During the course of treatment and follow-up,the recurrence of ischemic stroke in the two groups was compared.Results:In the course of trial,4 cases in the treatment group were excluded or dropped out,and 2 cases in the control group were excluded or dropped out.Finally,58 cases in the treatment group and 60 cases in the control group were included for statistical analysis.(1)After treatment and on the 90 th day of follow-up,the scores of NIHSS in the two groups were significantly decreased compared with those before treatment(P<0.01),and the score of the treatment group was lower than that of the control group(P<0.05,P<0.01).(2)After treatment and on the 90 th day of follow-up,the scores of mRS in the two groups were significantly improved compared with those before treatment(P<0.05),and the improvement of mRS score in the treatment group was better than that in the control group(P<0.05).(3)After treatment and on the 90 th day of follow-up,the scores of BI in the two groups were significantly increased compared with those before treatment(P<0

关 键 词：急性缺血性脑卒中 气虚血瘀型 芪龙祛瘀合剂 中西医结合 

分 类 号：R277.7[医药卫生—中医学]